1
|
McLoughlin A, Mulholland K, McMahon E, Plunkett R, Hennigan K, McDonald C, Hallahan B. A 2-year longitudinal evaluation of the impact of the COVID-19 pandemic on individuals with pre-existing anxiety disorders. Ir J Psychol Med 2023; 40:437-444. [PMID: 37051901 DOI: 10.1017/ipm.2023.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
OBJECTIVES To examine if the COVID-19 pandemic is associated with a differential effect over a 2-year time period in relation to its psychological and social impact on patients with established anxiety disorders. METHODS Semi-structured interviews were conducted with 21 individuals attending the Galway-Roscommon Mental Health Services in Ireland with an ICD-10 diagnosis of an anxiety disorder. Interviews occurred at three time-points over a 2-year period to determine the impact of the COVID-19 pandemic and associated restrictions on anxiety and depressive symptoms, social and occupational functioning, and quality of life. RESULTS No statistical difference in symptomatology was noted between the three time-points in relation to anxiety symptoms as measured utilising psychometric rating scales (Beck Anxiety Inventory (BAI), Hamilton Anxiety Rating Scale (HARS) or Likert Scale measures). The greatest impact of COVID-19 at all time-points related to social functioning and quality of life. Significant variability was noted for individual participants. Qualitative analysis noted a tentative optimism for the future in the setting of vaccination and societal re-opening. Fear of re-emerging anxiety symptoms with the removal of societal restrictions was noted. CONCLUSIONS No significant overall change in symptomatology or functioning over time was noted for individuals with pre-existing anxiety disorders, however variability was demonstrated, with some individuals describing ongoing anxiety, social isolation and concern for their future. A strong theme of hope for the future and less concern regarding the COVID-19 pandemic was evident; however tailored supports including the utilisation of tele-psychiatry is suggested, particularly for those experiencing increased anxiety with the removal of societal restrictions.
Collapse
Affiliation(s)
- A McLoughlin
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
- Department of Psychiatry, Jonathan Swift Centre, St. James's Hospital, Dublin8, Ireland
| | - K Mulholland
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
| | - E McMahon
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
| | - R Plunkett
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
- Department of Psychological Medicine, St. James's Hospital, Dublin8, Ireland
| | - K Hennigan
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
- Department of Psychiatry, Mayo University Hospital, Castlebar, Co. Mayo, Ireland
| | - C McDonald
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
- School of Medicine, University of Galway, Galway, Ireland
| | - B Hallahan
- Galway-Roscommon Mental Health Services, University Hospital Galway, Ireland
- School of Medicine, University of Galway, Galway, Ireland
| |
Collapse
|
2
|
Patel S, Bhhatarai B, Calses P, Erlanson D, Everley R, Fong S, Gerken P, Hermann JC, Le T, Liu LK, McMahon E, Neve RM, Phan T, Roberts A, Shanafelt M, Siemsgluess S, Staunton J, Wang Y, Wang W, Williams M, Webster KR. Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-1142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
KRAS is one of the most frequently mutated genes in cancer and was long considered undruggable until the recent discovery of inhibitors that bind the inactive (GDP-bound) form of KRASG12C. The most clinically advanced of these first-generation molecules have demonstrated clinical response rates of 30-45% and approximately 6-month progression-free survival in lung cancer patients. While significant, a majority of patients fail to achieve a clinical response and acquired resistance is common. Resistance to first-generation inhibitors can be driven by upregulation of the activated (GTP-bound) form of KRASG12C, which remains an undrugged form of the oncoprotein. Here we report the discovery of FMC-376, a novel inhibitor of the activated, GTP-bound, form of KRASG12C, which also potently inhibits the inactive, (GDP-bound), form of KRASG12C. FMC-376 was discovered through the FrontierTM platform, which integrates chemoproteomics, machine-learning, and covalent fragment-based drug discovery. FMC-376 binds KRAS in the switch II pocket, rapidly forming a covalent bond with cysteine 12 in the presence of either GDP or GTP. X-ray crystallography demonstrated that Cys12 adopts a novel confirmation in forming a covalent bond with FMC-376. This results in potent inhibition of RAF1 and PI3Kα effector interactions (IC50 = 0.007 μM for both respectively at 2 h) in contrast to sotorasib or adagrasib (IC50 > 50 and ~ 5 μM respectively). FMC-376 treatment results in potent anti-tumor activity across a panel of KRASG12C mutant tumor cell lines, sparing non- KRASG12C cell lines. To model resistance mediated by activated KRASG12C, a mutation that abrogates GTPase activity (A59G) was introduced into KRASG12C. This upregulation of GTP-bound KRASG12C drives significant (>10-fold) resistance to both adagrasib and sotorasib in tumor cell viability assays whereas FMC-376 remains equipotent in settings where GTP-bound KRASG12C is upregulated. Evaluation of FMC-376 in models where EGFR signaling (a suspected mechanism of clinical resistance) is induced demonstrated rapid and durable target engagement in contrast to both sotorasib and adagrasib which show decreased effectiveness after EGF stimulation. Further evaluation of FMC-376 in vivo has demonstrated rapid and durable KRASG12C target occupancy (>90%) and pathway inhibition in tumors, resulting in regression of CDX/PDX tumor models. FMC-376, an inhibitor of both active and inactive forms of KRASG12C, provides a differentiated mechanism of action with the potential for broader and more durable response in the clinic.
Citation Format: Snahel Patel, Barun Bhhatarai, Philamer Calses, Daniel Erlanson, Robert Everley, Susan Fong, Phil Gerken, Johannes C. Hermann, Tiep Le, Li-kai Liu, Evan McMahon, Richard M. Neve, Tony Phan, Allison Roberts, Mikayla Shanafelt, Sophie Siemsgluess, Jocelyn Staunton, Yan Wang, Weiru Wang, Monika Williams, Kevin R. Webster. Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1142.
Collapse
Affiliation(s)
| | | | | | | | | | - Susan Fong
- 1Frontier Medicines, South San Francisco, CA
| | - Phil Gerken
- 1Frontier Medicines, South San Francisco, CA
| | | | - Tiep Le
- 1Frontier Medicines, South San Francisco, CA
| | | | | | | | - Tony Phan
- 1Frontier Medicines, South San Francisco, CA
| | | | | | | | | | | | - Weiru Wang
- 1Frontier Medicines, South San Francisco, CA
| | | | | |
Collapse
|
3
|
Dason ES, Drost L, Greenblatt EM, Scheer AS, Han J, Sobel M, Allen L, Jacobson M, Doshi T, Wolff E, McMahon E, Jones CA. Providers' perspectives on the reproductive decision-making of BRCA-positive women. BMC Womens Health 2022; 22:506. [PMID: 36482357 PMCID: PMC9730610 DOI: 10.1186/s12905-022-02093-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 11/22/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Reproductive decision-making is difficult for BRCA-positive women. Our objective was to assess the complexities of decision-making and identify decisional supports for patients and providers when discussing reproductive options prior to risk-reducing salpingo-oophorectomy (RRSO). METHODS This study was of qualitive design, using data collection via semi-structured interviews conducted from November 2018 to October 2020. Individuals were included if they were identified to provide care to BRCA-positive women. In total, 19 providers were approached and 15 consented to participate. Providers were recruited from three clinics in Toronto, Ontario located at academic centers: [1] A familial ovarian cancer clinic, [2] A familial breast cancer clinic and [3] A fertility clinic, all of which treat carriers of the BRCA1/BRCA2 genetic mutation. The interview guide was developed according to the Ottawa Decision Support Framework and included questions regarding reproductive options available to patients, factors that impact the decision-making process and the role of decisional support. Interviews were transcribed and transcripts were analyzed thematically using NVIVO 12. RESULTS Providers identified three major decisions that reproductive-aged women face when a BRCA mutation is discovered: [1] "Do I want children?"; [2] "Do I want to take the chance of passing on this the mutation?"; and [3] "Do I want to carry a child?" Inherent decision challenges that are faced by both providers and patients included difficult decision type, competing options, scientifically uncertain outcomes, and challenging decision timing. Modifiable decisional needs included: inadequate knowledge, unrealistic expectations, unclear values and inadequate support or resources. Identified clinical gaps included counselling time constraints, lack of reliable sources of background information for patients or providers and need for time-sensitive, geographically accessible, and centralized care. CONCLUSION Our study identified a need for a patient information resource that can be immediately provided to patients who carry a BRCA genetic mutation. Other suggestions for clinical practice include more time during consultation appointments, adequate follow-up, value-centric counseling, access to psychosocial support, and a specialized decisional coach.
Collapse
Affiliation(s)
- E. S. Dason
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,Mount Sinai Fertility, 7th Floor, 250 Dundas St. W, Toronto, ON M5T 2Z5 Canada
| | - L. Drost
- grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| | - E. M. Greenblatt
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| | - A. S. Scheer
- grid.415502.7Department of General Surgery, St. Michaels Hospital, Unity Health Network, Toronto, ON M5B 1W8 Canada
| | - J. Han
- grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| | - M. Sobel
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada ,grid.417199.30000 0004 0474 0188Department of Obstetrics and Gynecology, Women’s College Hospital, Toronto, ON M5S 1B2 Canada
| | - L. Allen
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada ,grid.417199.30000 0004 0474 0188Department of Obstetrics and Gynecology, Women’s College Hospital, Toronto, ON M5S 1B2 Canada
| | - M. Jacobson
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada ,grid.417199.30000 0004 0474 0188Department of Obstetrics and Gynecology, Women’s College Hospital, Toronto, ON M5S 1B2 Canada
| | - T. Doshi
- grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| | - E. Wolff
- grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| | - E. McMahon
- grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada ,grid.17063.330000 0001 2157 2938Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON M5T 1P8 Canada
| | - C. A. Jones
- grid.17063.330000 0001 2157 2938Department of Obstetrics and Gynecology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1E2 Canada ,grid.492573.e0000 0004 6477 6457Department of Obstetrics and Gynecology, Mount Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5 Canada
| |
Collapse
|
4
|
Bosque A, Howard J, Zaikos T, Levinger C, McMahon E, Takata H, Rivera E, Copertino D, Wang W, Sanz-Perez M, Arias-Moreno X, Soriano-Sarabia N, Jones RB, Trautmann L. OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs. J Virus Erad 2022. [DOI: 10.1016/j.jve.2022.100236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
5
|
Calses P, Clark S, Corpuz J, Fong S, Gerkin P, Hekmatnejad M, McMahon E, Murray M, Nguyen T, Phan T, Roberts A, Schwartz P, Shanafelt M, Tanaka H, Tomczyk J, Widen J, Williams M, Eksterowicz J, Erlanson D, Evangelista M, Hermann J, Neve RM, Patel S, Webster KR. Abstract 3601: Discovery of novel dual-acting KRASG12C inhibitors that target both the active and inactive forms of the protein. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
KRAS is one of the most frequently mutated genes in cancer with alterations occurring in > 14% of all tumors. Recent advances have led to the discovery and development of inhibitors that bind the inactive (GDP-bound) form of KRASG12C. The most advanced of these first-generation molecules demonstrated clinical response rates of 30-45% and approximately 6-month progression-free survival in lung cancer patients. While significant, a majority of patients failed to achieve a clinical response and acquired resistance can be rapid. One hypothesis to explain tumor resistance is the failure of existing inhibitors to recognize the activated (GTP-bound) form of KRASG12C that can be upregulated in response to these first-generation inhibitors. Here we report the discovery of a series of novel inhibitors that effectively inhibit both the GTP- and GDP-bound forms of KRASG12C. These “dual-acting” inhibitors bind in the switch II pocket of both GTP-bound and GDP-bound KRASG12C and rapidly form a covalent bond with cysteine 12. This results in significantly increased inhibition of RAF1 and PI3Kα effector interactions (IC50 < 5 nM at 2 hrs.) in comparison to inactive state inhibitors. Dual targeting of both GTP- and GDP-bound KRASG12C results in potent cellular activity in models that are both sensitive (NCI-H358 and MIA PaCa-2) and resistant (NCI-H2122) to adagrasib and sotorasib. In contrast to adagrasib and sotorasib which are less effective in the NCI-H2122 cell line model, dual-acting inhibitors of GTP- and GDP-bound KRASG12C elicit rapid inhibition of pERK in < 1 hour with sustained inhibition of MAPK signaling through 48 hours. To model resistance to first generation inhibitors, an A59G mutation was introduced into KRASG12C, abrogating GTPase activity. This decreases the activity of both adagrasib and sotorasib in tumor cell viability assays by more than an order of magnitude whereas dual-acting inhibitors of GTP- and GDP-bound KRASG12C are equally effective in the G12C/A59G and parental G12C cell lines. Evaluation of dual-acting inhibitors of KRASG12C in vivo demonstrated rapid and > 90% KRASG12C target occupancy, resulting in regression of MIA PaCa-2 tumors. Dual-acting inhibitors of both the active and inactive states of KRASG12C may provide the potential for broader and more durable responses in the clinic.
Citation Format: Philamer Calses, Sam Clark, Jacob Corpuz, Susan Fong, Phil Gerkin, Mohammad Hekmatnejad, Evan McMahon, Megan Murray, Truc Nguyen, Tony Phan, Allison Roberts, Phillip Schwartz, Mikayla Shanafelt, Hiroko Tanaka, Jennifer Tomczyk, John Widen, Monika Williams, John Eksterowicz, Daniel Erlanson, Marie Evangelista, Johannes Hermann, Richard M. Neve, Snahel Patel, Kevin R. Webster. Discovery of novel dual-acting KRASG12C inhibitors that target both the active and inactive forms of the protein [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3601.
Collapse
Affiliation(s)
| | - Sam Clark
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Jacob Corpuz
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Susan Fong
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Phil Gerkin
- 1Frontier Medicines Corp, South San Francisco, CA
| | | | - Evan McMahon
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Megan Murray
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Truc Nguyen
- 1Frontier Medicines Corp, South San Francisco, CA
| | - Tony Phan
- 1Frontier Medicines Corp, South San Francisco, CA
| | | | | | | | | | | | - John Widen
- 1Frontier Medicines Corp, South San Francisco, CA
| | | | | | | | | | | | | | - Snahel Patel
- 1Frontier Medicines Corp, South San Francisco, CA
| | | |
Collapse
|
6
|
Jones CA, Hawkins L, Friedman C, Hitkari J, McMahon E, Born KB. Choosing Wisely Canada: Canadian fertility and andrology society’s list of top items physicians and patients should question in fertility medicine. Arch Gynecol Obstet 2022; 306:267-275. [PMID: 35278119 PMCID: PMC8917376 DOI: 10.1007/s00404-022-06453-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 02/10/2022] [Indexed: 11/24/2022]
Abstract
Purpose To create a Choosing Wisely Canada list of the top 5 diagnostic and therapeutic interventions that should be questioned in Reproductive Endocrinology and Infertility in Canada. Methods The Canadian Fertility and Andrology Society (CFAS) National Working Group developed an initial list of recommendations of diagnostic and therapeutic interventions that are commonly used, but are not supported by evidence, and could expose patients to unnecessary harm. These were chosen based on their prevalence, cost, potential for harm, and quality of supporting evidence. A modified Delphi consensus was used over 5 rounds to generate ideas, review supporting evidence, assess clinical relevance, estimate recommendation impact and narrow the recommendations list to 5 items. Results Fifty unique ideas were first proposed by the working group, and after 5 rounds including a survey of Canadian Fertility and Andrology Society (CFAS) members, the final list of recommendations was created, including topics related to unnecessary investigations and interventions for patients with infertility and recurrent pregnancy loss, and those undergoing IVF. In this article, we describe not only the Delphi process used to determine the list, but also provide a summary of the evidence behind each of the final recommendations. Conclusions The list of five recommendations highlights opportunities to initiate conversations between clinicians and patients about the risks, benefits, harms and costs of unnecessary fertility treatments and procedures in a Canadian context.
Collapse
Affiliation(s)
- C A Jones
- Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward St, Toronto, ON, M5G 1E2, Canada
- Mount Sinai Fertility, Sinai Health System, 700-250 Dundas Street West, Toronto, ON, M5T 2Z5, Canada
| | - L Hawkins
- Department of Obstetrics and Gynaecology, University of Toronto, 123 Edward St, Toronto, ON, M5G 1E2, Canada
- Department of Obstetrics and Gynaecology, Humber River Hospital, 1235 Wilson Ave, North York, ON, M3M 0B2, Canada
| | - Catherine Friedman
- Department of Obstetrics and Gynaecology, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
| | - J Hitkari
- Department of Obstetrics and Gynaecology, University of British Columbia, 930-1125 Howe Street, Vancouver, BC, V6Z 2K8, Canada
- Olive Fertility Centre, 300-East Tower, 555 West 12th Avenue, Vancouver, BC, V5Z 3X7, Canada
| | - E McMahon
- Mount Sinai Fertility, Sinai Health System, 700-250 Dundas Street West, Toronto, ON, M5T 2Z5, Canada
- Bloomberg Faculty of Nursing, University of Toronto, 155 College Street, Suite 130, Toronto, ON, M5T 1P8, Canada
| | - K B Born
- Institute of Health Policy, Management and Evaluation, Dalla School of Public Health, University of Toronto, 155 College St. 4th Floor, Toronto, ON, M5T 3M6, Canada
| |
Collapse
|
7
|
Brimblecombe J, McMahon E, De Silva K, Ferguson M, Miles E, Wycherley T, Peeters A, Minaker L, Greenacre L, Mah C. Transforming food retail for better health: The Healthy Stores 2020 trial. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
How food is promoted in food retail settings impacts population diet. Foods high in sugar, fat and/or salt are promoted by retailers to attract impulse purchases. To combat the high burden of chronic disease and associated conditions confronting society we examined the impact of restricted retail merchandising (promotion and visibility) of discretionary food and beverages on sales and business outcomes.
Methods
We conducted a pragmatic randomised controlled trial in partnership with a retail organisation operating stores in remote communities of Australia (the Arnhem Land Progress Aboriginal Corporation). Twenty consenting stores were allocated to the 12-week intervention (7-point Healthy Stores 2020 strategy) or to usual retail practice. Four intervention stores with retail competition implemented a modified 6-point strategy. Weekly sales data were used to assess intervention impact on free sugars (g) to energy (MJ) (primary outcome) derived from all purchased food and beverages. Impact on gross profit and sales of targeted food and beverages was also assessed. Managers of intervention stores were interviewed to determine their views on customer response and impact on retail practice.
Results
Free sugars were reduced by a relative 2.8% (95% CI -4.8, -0.7). There were significant reductions in free sugars from targeted beverages (-6.4%; -11.1, -1.5) and soft drinks (-12.5%; -18.1, -6.5). Gross profit was not impacted adversely. Managers mostly viewed the strategy favourably and of benefit to the community.
Conclusions
The public health and business relevant gains demonstrated by this novel trial have resulted in ALPA converting their stores to the Healthy Stores 2020 strategy and integrating the strategy in to their nutrition policy. Retail competition impedes complete implementation of the 7-point strategy. Tackling this will require collective agreement by retailers to implement the full strategy and/or government policy power.
Key messages
Restricting merchandising of unhealthy foods can achieve both public health relevant and business relevant gains. Working in partnership with retailers is critical to testing real-world interventions to impact population diet.
Collapse
Affiliation(s)
- J Brimblecombe
- Public Health Nutrition, Department of Nutrition, Dietetics and Food, Monash University, Victoria, Australia
| | - E McMahon
- Wellbeing and Preventable Chronic Disease, Menzies School of Health Research, Brisbane, Australia
| | - K De Silva
- Arnhem Land Progress Aboriginal Corporation, Darwin, Northern Territory, Australia
| | - M Ferguson
- Public Health Nutrition, The University of Queensland, Brisbane, Queensland, Australia
| | - E Miles
- Menzies School of Health Research, Darwin, Australia
| | - T Wycherley
- School of Health Sciences, University of South Australia, Adelaide, Australia
| | - A Peeters
- Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia
| | - L Minaker
- University of Waterloo, Waterloo, Ontario, Canada
| | - L Greenacre
- Department of Marketing, Monash University, Victoria, Australia
| | - C Mah
- Dalhousie University, Halifax, Nova Scotia, Canada
| |
Collapse
|
8
|
McMahon E, Barzi F, Gunther A, Webster J, Brimblecombe J. Reducing salt in bread does not affect sales in remote indigenous community stores. Journal of Nutrition & Intermediary Metabolism 2017. [DOI: 10.1016/j.jnim.2017.04.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
9
|
McMahon E, Clarke R, Jaenke R, Brimblecombe J. Acceptability of reduced salt bread in a remote Indigenous Australian community. Journal of Nutrition & Intermediary Metabolism 2016. [DOI: 10.1016/j.jnim.2015.12.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
McMahon E, Keeley H, Cannon M, Arensman E, Perry I, Clarke M, Chambers D, Corcoran P. OP23 The Iceberg of suicide and self-harm in irish adolescents – a population-based study. Br J Soc Med 2015. [DOI: 10.1136/jech-2015-206256.23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
11
|
Irvine AB, Billow MB, McMahon E, Eberhage MG, Seeley JR, Bourgeois M. Mental illness training on the Internet for nurse aides: a replication study. J Psychiatr Ment Health Nurs 2013; 20:902-12. [PMID: 23379724 PMCID: PMC3655099 DOI: 10.1111/jpm.12035] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/07/2013] [Indexed: 10/27/2022]
Abstract
Internet training courses for nurse aides (NAs) in long-term care facilities (LTCs) have been shown to be effective. Little is known, however, about Internet training effects on NAs in a non-research context, or about continued utilization of an available training programme. In this research, a replication study was conducted with the Internet training programme Caring Skills: Working with Mental Illness. Three LTCs provided the training to all NAs, each within a 1-month interval scheduled during consecutive months. Supervisors were interviewed subsequently about their experiences organizing and supervising the training. Participants in all three LTCs showed positive pre-post-tests effects with large effect sizes on situational knowledge and self-efficacy, and knowledge about mental illness. Users rated the programme highly, and they indicated that it would improve quality of their resident care. Supervisors praised the training, and they said NAs were using recommended training behaviours. Although available to all staff, nursing and other staff made little use of the training in subsequent months. Training for NAs on the Internet thus appears feasible, and it is perceived to be beneficial for resident care. Plans for continued utilization and dissemination of best practices to other staff, however, should be integrated when planning for staff training on the Internet.
Collapse
|
12
|
Chen R, Chen M, Zhang Y, McMahon E, Loffredo M, Nguyen P, Beard C, D'Amico A. Patient-reported Quality of Life (QOL) in Unfavorable-Risk Prostate Cancer: Sexual Function Recovery after External Beam Radiation (RT) and 6 months of Androgen Deprivation. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
D'Amico A, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang N, Small E, Kantoff P. p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1406] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Kumar P, McMahon E, Panaitescu A, Willingale R, O'Brien P, Burrows D, Cummings J, Gehrels N, Holland S, Pandey SB, Vanden Berk D, Zane S. The nature of the outflow in gamma-ray bursts. ACTA ACUST UNITED AC 2007. [DOI: 10.1111/j.1365-2966.2007.00286.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Woel R, Beard C, Chen M, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D’Amico A. Acute gastrointestinal, genitourinary, and dermatologic toxicity during dose escalated 3DCRT using an intra-rectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 2004. [DOI: 10.1016/j.ijrobp.2004.07.559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, McMahon E, Renshaw AA, Tomaszewski JE, D'Amico AV. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. L. Nguyen
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - R. Whittington
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - S. Koo
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - D. Schultz
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - K. B. Cote
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - M. Loffredo
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - E. McMahon
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - A. A. Renshaw
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - J. E. Tomaszewski
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| | - A. V. D'Amico
- Harvard Medical School, Boston, MA; University of Pennsylvania Radiation Oncology, Philadelphia, PA; Millersville University Dept of Mathematics, MIllersville, PA; Brigham & Womens/Dana-Farber Radiation Oncology, Boston, MA; Baptist Hospital of Miami Dept of Pathology, Miami, FL; University of Pennsylvania Dept of Pathology, Philadelphia, PA
| |
Collapse
|
17
|
Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96:2973-80. [PMID: 11049973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
To investigate the mechanism by which macrophage inflammatory protein-1alpha (MIP-1alpha) affects graft-versus-host disease (GVHD), the expression and function of MIP-1alpha in 2 murine models of GVHD were evaluated. In irradiated class I and class II disparate recipients, the expression of messenger RNA (mRNA) and protein for MIP-1alpha was significantly increased in GVHD target organs after transfer of allogeneic lymphocytes compared to syngeneic lymphocytes. When lymphocytes unable to make MIP-1alpha were transferred, there was a decrease in the production of MIP-1alpha in the liver, lung, and spleen of bm1 (B6.C-H2(bm1)/By) and bm12 (B6.C-H2(bm12)/KhEg) recipients compared to the transfer of wild-type splenocytes. At day 6 there was a 4-fold decrease in the number of transferred CD8(+) T cells in the lung and approximately a 2-fold decrease in the number of CD8(+) T cells in the liver and spleen in bm1 recipients after transfer of MIP-1alpha-deficient (MIP-1alpha(-/-)) splenocytes compared to wild-type (MIP-1alpha(+/+)) splenocytes. These differences persisted for 13 days after splenocyte transfer. In contrast, the number of donor CD4(+) T cells found in the liver and lung was significantly increased after the transfer of MIP-1alpha(-/-) compared to wild-type splenocytes in bm12 recipients from day 6 through day 10. Thus, the transfer of allogeneic T cells was associated with the enhanced expression of MIP-1alpha in both a class I and class II mismatch setting. However, the increased expression only led to enhanced recruitment of CD8(+), but not CD4(+), donor T cells. Production of MIP-1alpha by donor T cells is important in the occurrence of GVHD and functions in a tissue-dependent fashion.
Collapse
Affiliation(s)
- J S Serody
- Departments of Medicine, Microbiology, and Immunology, University of North Carolina School of Medicine, the Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599-7295, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Wu YP, McMahon E, Kraine MR, Tisch R, Meyers A, Frelinger J, Matsushima GK, Suzuki K. Distribution and characterization of GFP(+) donor hematogenous cells in Twitcher mice after bone marrow transplantation. Am J Pathol 2000; 156:1849-54. [PMID: 10854208 PMCID: PMC1850087 DOI: 10.1016/s0002-9440(10)65058-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The twitcher mouse is a murine model of globoid cell leukodystropy, a genetic demyelinating disease caused by a mutation of the galactosylceramidase gene. Demyelination of the central nervous system commences around 20 postnatal days. Using GFP-transgenic mice as donors, the distribution of hematogenous cells after bone marrow transplantation was investigated in the twitcher mice. Bone marrow transplantation was carried out at 8 postnatal days. In twitcher chimeric mice examined before 30 postnatal days, numerous GFP(+) cells were detected in spleen and peripheral nerve but only a few were detected in the liver, lung, and spinal white matter. In contrast, at 35 to 40 postnatal days when demyelination is evident, many GFP(+) cells with ameboid form were detected in the white matter of the spinal cord, brainstem, and cerebrum. Approximately half of these GFP(+) cells were co-labeled with Mac-1. In twitcher chimeric mice examined after 100 postnatal days, the majority of GFP/Mac-1 double-positive cells displayed the morphological features of ramified microglia with fine delicate processes and was distributed diffusely in both gray and white matter. These results suggest that a significant number of donor hematogenous cells are able to infiltrate into the brain parenchyma, repositioning themselves into areas previously occupied by microglia, and to ameliorate lethality.
Collapse
Affiliation(s)
- Y P Wu
- Department of Pathology and Laboratory Medicine, the University of North Carolina, Chapel Hill 27599-7525, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Affiliation(s)
- R K Kaminer
- Children's Evaluation and Rehabilitation Center of Albert, Einstein College of Medicine, Bronx NY
| | | |
Collapse
|
20
|
Bovy PR, O'Neal JM, McMahon E, Palomo M, Smits GJ, Trapani AJ, McGraw D. Synthesis and biological activity of N-terminus modified [Ile8] angiotensin II analogues. Eur J Med Chem 1990. [DOI: 10.1016/0223-5234(90)90183-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
21
|
|
22
|
McMahon E. The Michigan hospice MD. Mich Med 1981; 80:180. [PMID: 7231208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
23
|
McMahon E, Carr PF, Clarke JKA. Exchange reaction between cyclopentane and deuterium on evaporated nickel–copper alloy films. ACTA ACUST UNITED AC 1971. [DOI: 10.1039/j19710002012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|